Vivo Capital — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Inspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform.
BiotechHealthtechMedical DevicesNew York, US
Sohail Tavazoie(Co-Founder & Chair of Scientific Advisory Board)Masoud Tavazoie(Co-Founder & Advisor)in
Co-investorsSofinnova PartnersSands Capital VenturesStart CapitalNovo Holdings
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalF-Prime CapitalJeito CapitalLongwood FundSR One Capital ManagementSV Health Investors+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.